Second Genome Overview
Founded
2009
Status
Private
Employees
58
Latest Deal Type
Grant
Latest Deal Amount
$1.13M
Investors
15
Second Genome General Information
Description
Provider of microbial profiling services designed to develop improved ways for treating chronic disease and illness. The company's microbiome data platform utilizes microbiome biology, bioinformatics, computation and machine learning to identify prospective therapeutic lead candidates, bacteria, peptides and metabolites which benefit human health, enabling therapeutic candidates to be advanced through pharmaceutical clinical programs.
Contact Information
Website
Formerly Known As
Phylotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 341 Allerton Avenue
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Second Genome Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 01-Jan-2019 | $1.13M | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 4. Later Stage VC (Series B) | 13-Apr-2016 | 000.00 | 000.00 | 0000 | Completed | Clinical Trials - Phase 1 |
| 3. Early Stage VC (Series A) | 07-Jun-2013 | 000.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series A) | 09-Aug-2011 | $5M | $6.24M | 000.00 | Completed | Startup |
| 1. Seed Round | 07-Jul-2010 | $1.24M | $1.24M | 00.00 | Completed | Startup |
Second Genome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed | 5,607,290 | $0.000100 | $0.02 | $0.22 | $0.22 | 1x | $0.22 | 2.12% |
Second Genome Competitors (28)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pendulum Therapeutics | Venture Capital-Backed | San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 000000000 | Venture Capital-Backed | Vancouver, Canada | 000 | 00000 | 00000000000 | 00000 |
| 00000000 000000 | Venture Capital-Backed | Emeryville, CA | 000 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 0000000000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Somerville, MA | 00 | 00000 | 00000000000 | 00000 |
Second Genome Executive Team (15)
10 Former Executives
Second Genome Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bradley Margus | Self | Board Member | 000 0000 |
| Carole Nuechterlein JD | Roche Venture Fund | Board Member | 000 0000 |
| Corey Goodman Ph.D | Self | Co-Founder & Chairman | 000 0000 |
| Elaine Jones Ph.D | Pfizer Ventures | Board Member | 000 0000 |
| Geoffrey Smith JD | Digitalis Ventures | Board Observer | 000 0000 |
3 Former Board Members
Second Genome Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| Digitalis Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Lifeforce Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Lifeforce Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Lightstone Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
Ready to get started?
Request a free trial